Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026

Same author

LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.

Oncogene·2026

Same author

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Blood cancer discovery·2026

Same author

Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma.

Blood cancer discovery·2026

Same author

CD28⁺ CD8⁺ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.

Blood·2026

Same author

CSNK1E sustains stemlike drug persistence in diffuse large B-cell lymphoma.

Blood·2026

Same journal

Arterial iron regulates vasodilation during anemia via endothelial holo α-globin.

Blood·2026

Same journal

One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype.

Blood·2026

Same journal

NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.

Blood·2026

Same journal

Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistance.

Blood·2026

Same journal

FGF18 mediates fibroblast-leukemia crosstalk to promote acute myeloid leukemia progression.

Blood·2026

Same journal

Iron in HSCs: too much of a good thing.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 23, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.

Song Hu¹, Yao Qin², Hong-Mei Yi³

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong, Shanghai, China.

|May 21, 2026

Summary

This summary is machine-generated.

IGF2BP2 promotes aggressive Peripheral T-cell lymphoma (PTCL) growth by enhancing endocytosis and suppressing immune cells. Targeting IGF2BP2 offers a new therapeutic strategy for PTCL by inhibiting tumor growth and immune evasion.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 23, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Area of Science:

Oncology
Molecular Biology
Immunology

Background:

Peripheral T-cell lymphoma (PTCL) is an aggressive cancer with limited therapeutic targets.
RNA modification pathways, particularly N6-methyladenosine (m6A), are implicated in cancer development.
IGF2BP2 is an m6A reader involved in oncogenesis.

Purpose of the Study:

To investigate the role of IGF2BP2 in PTCL pathogenesis.
To explore IGF2BP2 as a potential therapeutic target in PTCL.

Main Methods:

Analysis of IGF2BP2 expression in PTCL patient cohorts.
In vitro and in vivo experiments using cell lines and patient-derived xenografts.
RNA sequencing (RNA-seq) to identify downstream targets.
Co-culture systems with PTCL cells and immune cells.

Main Results:

High IGF2BP2 expression was observed in PTCL subtypes.
IGF2BP2 promotes tumor cell proliferation and inhibits CD8+ T cell infiltration.
IGF2BP2 regulates endocytosis by stabilizing endosome-related genes.
Targeting IGF2BP2 with CWI1-2 suppressed tumor growth and endocytosis.

Conclusions:

IGF2BP2 is a key oncogenic driver in PTCL, regulating both tumor growth and immune suppression.
IGF2BP2's role in endocytosis presents a novel mechanism for immune evasion in PTCL.
Targeting IGF2BP2 represents a promising RNA modification-based therapeutic strategy for PTCL.